I AM ALS, The ALS Association renew call for FDA, Amylyx to make AMX0035 available to people with ALS
For Immediate Release: Oct. 16, 2020
Contact: Theresa Garner, [email protected]
WASHINGTON, DC — The findings from the open label extension (OLE) study of AMX0035 further show that the treatment should be made available to people with ALS as soon as possible. People participating in the OLE study appeared to live several months longer than they would have without AMX0035. These findings were in addition to the findings reported last month showing a significant functional benefit to people with ALS. We urge the FDA and Amylyx to work together to bring this treatment to market as soon as possible and we stand ready to help ensure that happens. We invite anyone who hasn’t already signed the petition to the FDA and Amylyx to do so at als.org/petition
About I AM ALS
I AM ALS is a patient-centric movement revolutionizing how to fight disease. The non-profit brings together ALS patients, advocates, organizations and researchers to deliver critical and innovative resources for patients, empower and mobilize patients and their networks to lead the fight for cures and transform the public understanding of ALS with a goal of delivering new, lifesaving drugs. Founded in 2019 by husband and wife team Brian Wallach and Sandra Abrevaya, I AM ALS was born out of their desire to rewrite the ALS story for Brian and the tens of thousands of other ALS patients. Learn more at iamals.org.
ALS is a disease that attacks cells in the body that control movement. It makes the brain stop talking to the muscles, causing increased paralysis over time. Ultimately, ALS patients become prisoners within their own bodies: unable to eat, talk, breathe or move on their own. Their mind, however, often remains sharp so they are aware of what’s happening to them. ALS will affect 1 in 300 people in our lifetimes, and patients usually have no more than 3 years to live following diagnosis.